Compare Heron Therapeutics Inc (HRTX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Target Corporation — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Target Corporation trades at $153.08 (market cap $69.17B). The key difference: Target Corporation is far larger — about 1125.3× Heron Therapeutics Inc's market cap, and Target Corporation pays a 3.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TGT | |
|---|---|---|
Market Cap | $61.47M | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $152.35 |
52-Week Low | $0.32 | $83.68 |
Enterprise Value | $168.21M | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Target Corporation (TGT) trades at $152.85, up 0.5% today, near its 52-week high. The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue remains stable around $106 billion, with a net income margin of 3.24% and solid cash flow from operations of $7.37 billion in 2025. Recent news includes the appointment of a chief AI officer, highlighting strategic focus on technology.
The outlook is positive with analyst consensus leaning buy, though valuation multiples like P/E of 20.12 suggest fair pricing. Risks include competitive retail pressures and macroeconomic sensitivity. Upside potential exists if AI initiatives drive efficiency, but investors should monitor Q2 2026 earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
